{"nctId":"NCT02822794","briefTitle":"Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen","startDateStruct":{"date":"2016-07-25","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":117,"armGroups":[{"label":"SOF/VEL FDC + RBV 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL","Drug: RBV"]},{"label":"SOF/VEL FDC + RBV 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL","Drug: RBV"]}],"interventions":[{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]},{"name":"RBV","otherNames":["REBETOL®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Genotype 1 or 2 HCV infection\n* Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical history or liver biopsy\n* Previously treated with a DAA-containing regimen of at least 4 week duration\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null},{"groupId":"OG001","value":"70.0","spread":null},{"groupId":"OG002","value":"97.9","spread":null},{"groupId":"OG003","value":"91.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)","description":"SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.0","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)","description":"SVR 24 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 1","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 2","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"70.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 3","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 4","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 5","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 6","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 8","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 10","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 12","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 16","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 20","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 24","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 1","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.40","spread":"0.640"},{"groupId":"OG001","value":"-4.36","spread":"0.698"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.91","spread":"0.510"},{"groupId":"OG001","value":"-4.89","spread":"0.603"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 3","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.07","spread":"0.506"},{"groupId":"OG001","value":"-5.02","spread":"0.575"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 4","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.486"},{"groupId":"OG001","value":"-5.04","spread":"0.580"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 5","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.487"},{"groupId":"OG001","value":"-5.05","spread":"0.579"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.492"},{"groupId":"OG001","value":"-5.05","spread":"0.579"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 8","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.492"},{"groupId":"OG001","value":"-5.06","spread":"0.584"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 10","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.492"},{"groupId":"OG001","value":"-5.06","spread":"0.589"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.492"},{"groupId":"OG001","value":"-5.06","spread":"0.589"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 16","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"0.594"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 20","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"0.594"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"0.594"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Viral upper respiratory tract infection","Anaemia","Headache","Stomatitis","Nausea"]}}}